Depression is among the most burdensome psychiatric conditions worldwide, and a substantial proportion of patients also suffer from gastrointestinal complaints ranging from slowed digestion to impaired barrier function. Current antidepressant therapies, including selective serotonin reuptake inhibitors such as fluoxetine, often deliver suboptimal efficacy and can themselves produce gastrointestinal side effects. That therapeutic gap motivated the research team, led by Li Fan and Qingwei Zhao of the First Affiliated Hospital of Zhejiang University School of Medicine, together with colleagues at Shanghai Jiao Tong University and Central South University, to investigate whether a natural product with a long history of use could act on both the brain and the gut simultaneously.

The team built their study on a chronic restraint stress mouse model, an established paradigm in which animals subjected to prolonged physical restraint develop behavioral and physiological hallmarks that mirror human depression, including gut dysfunction. Mice were divided into five groups: an unstressed control group, a stressed model group, a stressed group treated with the standard antidepressant fluoxetine, and two stressed groups treated with low or high doses of the Cistanche tubulosa total glycosides. All treatments were delivered orally by intragastric gavage over five weeks, a duration chosen to capture both the development of symptoms and the potential for therapeutic reversal.

The behavioral results were striking. Stressed mice that received the glycosides showed a robust restoration of sucrose preference, a standard measure of anhedonia, the loss of pleasure that defines depression. They also displayed increased locomotor activity and greater exploration of the central zones of an open field, both indicators of reduced anxiety-like behavior, and they spent less time immobile in the forced swimming test, another widely used index of behavioral despair. In short, the treated animals looked, by multiple independent behavioral yardsticks, substantially less depressed than their untreated stressed counterparts.

Equally important, the glycosides repaired the gut. Chronically stressed mice typically exhibit multi-segment intestinal dysmotility, and the untreated animals in this study showed prolonged total gut transit time, impaired colonic propulsion, and reduced gastric emptying and intestinal transit rates. Glycoside treatment shortened total transit time, restored colonic propulsion, and enhanced both gastric emptying and intestinal transit. Beyond motility, the treatment preserved the structural integrity of the intestinal barrier: microscopic examination revealed less epithelial damage, and molecular assays showed restored expression of tight junction proteins ZO-1 and occludin as well as the protective mucus component MUC2, all of which are critical to keeping the gut lining sealed against microbial and inflammatory assault.

Inflammation, a well-recognized link between gut dysfunction and mood disorders, also receded under treatment. Levels of the pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 dropped in the intestine, in the serum, and in the hippocampus, the brain region central to emotion and stress regulation. This coordinated reduction across gut, blood, and brain suggests that calming the intestine may send anti-inflammatory signals system-wide, a concept increasingly central to gut-brain axis research. The finding is consistent with the hypothesis that peripheral inflammation contributes to depressive symptomatology and that targeting the gut can modulate neuroinflammation.

To uncover the biochemical pathway underlying these effects, the researchers turned to untargeted metabolomics, an unbiased technique that measures thousands of small molecules simultaneously. The analysis pinpointed arachidonic acid metabolism as the key altered pathway. Treatment with the glycosides decreased cecal levels of arachidonic acid and 20-hydroxy-leukotriene B4 while increasing levels of dinoprost, metabolites with established connections to ferroptosis, an iron-dependent form of regulated cell death driven by the accumulation of lipid peroxides. Ferroptosis has attracted intense scientific interest in recent years because of its roles in neurodegeneration, inflammatory disease, and cancer, but its contribution to gut-brain comorbidity had remained poorly understood.

The mechanistic picture sharpened further with biochemical and molecular assays. The glycosides suppressed intestinal oxidative stress and lipid peroxidation, reduced the accumulation of ferrous iron, and reversed two signature changes in ferroptosis-related proteins: chronic stress had upregulated ACSL4, an enzyme that channels polyunsaturated fatty acids such as arachidonic acid into the lipid pools vulnerable to peroxidation, and had downregulated GPX4, the glutathione-dependent enzyme that normally detoxifies those lipid peroxides. Treatment normalized both. Molecular docking simulations added a final piece: echinacoside, one of the major constituents of the extract, showed strong predicted binding affinity for ACSL4, suggesting a direct molecular interaction that could explain how the glycosides restrain the ferroptotic machinery.

Taken together, the study proposes a coherent and novel pharmacological model. Chronic stress disrupts arachidonic acid metabolism in the gut, fueling ACSL4-mediated ferroptosis that damages the intestinal epithelium, weakens the barrier, and triggers inflammatory cytokine release that reaches the brain. Total glycosides from Cistanche tubulosa intervene at the intestinal source, suppressing ferroptosis, restoring barrier integrity, reducing inflammation, and thereby alleviating depressive-like behaviors. The authors suggest this gut-targeted pathway highlights the potential of these natural compounds as a basis for interventions aimed at comorbid depression and intestinal dysfunction. As with all preclinical work, the findings await validation in human trials, and questions remain about dosing, bioavailability, and long-term safety. Nevertheless, the study adds Cistanche tubulosa glycosides to a growing list of natural products whose effects on ferroptosis and the gut-brain axis are reshaping the search for next-generation antidepressant strategies, and it underscores a message increasingly echoed across neuroscience: to heal the mind, it may sometimes be necessary to begin with the gut.

Subject of Research: Suppression of intestinal ACSL4-mediated ferroptosis by Cistanche tubulosa glycosides to treat comorbid depression and intestinal dysfunction

Article Title: Glycosides from Cistanche tubulosa suppress intestinal ACSL4-mediated ferroptosis to ameliorate depression with intestinal dysfunction symptoms through regulating arachidonic acid metabolism

Article References: Fan, L., Shi, X., Zhao, L., Liu, J., Yang, X., Li, X., & Zhao, Q. (2026). Glycosides from Cistanche tubulosa suppress intestinal ACSL4-mediated ferroptosis to ameliorate depression with intestinal dysfunction symptoms through regulating arachidonic acid metabolism. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05602-0

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05602-0

Keywords: Cistanche tubulosa, glycosides, depression, intestinal dysfunction, ferroptosis, ACSL4, GPX4, arachidonic acid metabolism, gut-brain axis, echinacoside, chronic stress, intestinal barrier

The research, led by Cara L. Booker and colleagues at the University of Essex and published in SSM – Population Health, combines a systematic review of 428 population-based studies with an empirical analysis of more than 17,000 adults drawn from four major cohort studies: the English Longitudinal Study of Ageing, the Health and Retirement Study in the United States, the Midlife in the United States study, and Understanding Society, the UK Household Longitudinal Study. The team’s central question was deceptively simple: how much does allostatic load, as currently measured, actually overlap with multimorbidity, the co-occurrence of two or more long-term health conditions in the same individual? The answer matters because allostatic load is supposed to represent early, subclinical physiological dysregulation, while multimorbidity is a clinical endpoint. If the two constructs are largely the same thing in practice, thousands of studies interpreting allostatic load as a distinct marker of chronic stress may be measuring something rather different.

The systematic review, which screened 9,892 records and followed PRISMA 2020 guidelines, revealed striking inconsistency in how the construct is operationalised. Across the 428 included papers, the number of biomarkers used ranged from two to 28, spanning one to seven physiological systems. Cardiovascular and metabolic markers dominated: 410 of 428 studies included both metabolic and cardiovascular systems, while far fewer incorporated the primary neuroendocrine mediators that sit at the heart of allostatic theory. Systolic blood pressure appeared in 396 studies, diastolic blood pressure in 362, and C-reactive protein in 317. Despite this heavy reliance on a small core of markers, no consensus set of biomarkers has emerged, and the most common scoring approach remained a simple count of high-risk values.

The review’s most revealing findings concerned thresholds. When researchers use sample-based cut-points, typically the highest-risk quartile of their own study population, those thresholds can drift relative to established clinical criteria. The review found that quantile-based cut-offs for diastolic blood pressure averaged 83 mmHg, above the clinical threshold of 80 mmHg, and fasting glucose cut-offs averaged 7.4 mmol/L, exceeding the clinical 7 mmol/L. For body mass index, the typical quantile cut-off of 28.5 kg/m² sat well above the overweight threshold of 25. By contrast, sample-based thresholds for HbA1c, LDL cholesterol and total cholesterol fell below their clinical values. In other words, depending on the biomarker, a ‘high-risk’ allostatic load score may either exceed diagnostic criteria or remain comfortably within the normal range, positioning the index at very different points along the continuum from subclinical dysregulation to overt disease.

Medication use compounds the problem. Older adults frequently take antihypertensives, statins and glucose-lowering drugs that pharmacologically normalise the very biomarkers allostatic load indices count. A recent multi-cohort consensus statement warned that blood pressure and cholesterol, the ‘mainstays’ of allostatic load, may be inappropriate components in studies of older adults unless medication is explicitly considered. Yet the new review found that only about 36 percent of studies reported how medications were handled. Among those that did, most simply assigned participants taking relevant medication to the highest-risk category for that biomarker, a reasonable correction on its face, but one that injects diagnostic information directly into the exposure.

To test these concerns empirically, the team constructed eight different versions of allostatic load within each cohort: counts of high-risk biomarkers using sample quartiles or clinical cut-points, with and without medication adjustment, a pooled common-biomarker index, and a brief five-item score based on C-reactive protein, resting heart rate, HDL cholesterol, waist-to-height ratio and HbA1c, as recommended by the recent consensus statement. They then quantified overlap with three outcomes, general multimorbidity, cardiometabolic multimorbidity and immune multimorbidity, using C-statistics from logistic regression models adjusted for age, sex, ethnicity and survey year. C-statistics measure how well the allostatic load score discriminates between people with and without multimorbidity, with values above 0.8 indicating high overlap and values near 0.5 indicating none.

The results showed moderate-to-high overlap across the board. C-statistics ranged from roughly 0.68 to 0.82 for general multimorbidity, 0.69 to 0.86 for cardiometabolic multimorbidity, and 0.64 to 0.77 for immune multimorbidity. Strikingly, the different operationalisation strategies, sample quartiles, clinical thresholds, pooled biomarkers and the simplified five-item index, performed nearly identically, echoing earlier evidence that scoring algorithms differ little in predictive power. This convergence suggests that all current approaches draw on essentially the same metabolic and cardiovascular information, and that the brief five-item score captures little that longer biomarker batteries do not. The authors argue this reflects a broader feature of allostatic load research: indices are driven by downstream metabolic and inflammatory alterations rather than by the dynamic regulatory processes the theory describes.

Medication adjustment made things worse rather than better from a construct-validity standpoint. Incorporating medication information raised C-statistics in all four cohorts, with increases of up to +0.15 in the ageing studies ELSA and HRS, and the effect was largest for cardiometabolic multimorbidity. Because cardiometabolic conditions, including diabetes, hypertension, coronary heart disease and stroke, are defined by exactly the biomarker abnormalities that populate allostatic load indices, overlap with cardiometabolic multimorbidity exceeded that with general or immune multimorbidity in nearly every specification. Overlap with immune multimorbidity, covering conditions such as asthma, arthritis, chronic lung disease and thyroid disease, was consistently lower, likely reflecting the scarcity of inflammatory biomarkers and the absence of established cut-points for many of them. The pattern implies that what allostatic load most strongly detects is cardiometabolic disease itself, not a distinct stress-driven process preceding it.

The authors are careful to note that the overlap does not invalidate allostatic load as a concept. Multimorbidity may represent the clinical endpoint of allostatic processes, with chronic stress shifting physiological set points over time until dysregulation crosses into diagnosable disease. Cross-sectional measurement, however, cannot disentangle whether elevated allostatic load scores reflect the physiological embodiment of existing conditions or a shared pathophysiology, and the study’s reliance on data collected between 2004 and 2012 in predominantly White UK and US samples limits generalisability. The authors also acknowledge that C-statistics capture only one dimension of construct alignment and that complete-case analyses were used rather than multiple imputation.

The practical implications are nonetheless substantial. The authors recommend that researchers explicitly state where their chosen operationalisation sits on the subclinical-to-clinical continuum, consider sociodemographic influences on biomarker levels, including sex- and ethnicity-specific thresholds such as those proposed for BMI, and align medication-handling decisions with the analytical goal: identifying disease states or characterising latent physiological dysregulation. More fundamentally, they call for longitudinal designs, life-course biomarker collection and greater transparency in threshold definition. Until then, the study suggests, an index hailed as the biology of chronic stress may, in many published analyses, be functioning in practice as a partial census of diagnosed disease, a distinction that could reshape how hundreds of findings linking stress to health are interpreted.

Subject of Research: The conceptual and analytic overlap between allostatic load and multimorbidity

Article Title: A systematic review and empiric examination of the conceptual and analytic overlap between allostatic load and multimorbidity

Article References: A systematic review and empiric examination of the conceptual and analytic overlap between allostatic load and multimorbidity. (n.d.). https://doi.org/10.1016/j.ssmph.2026.101962

Image Credits: AI Generated

DOI: 10.1016/j.ssmph.2026.101962

Keywords: allostatic load, multimorbidity, chronic stress, biomarkers, cardiometabolic disease, physiological dysregulation, medication adjustment, clinical cut-points, population health, systematic review, ageing, cohort studies

The researchers examined a substantial demographic, concentrating on Americans aged 65 years and older. Among this population, they found that one in nine individuals who had faced parental divorce during their formative years reported being diagnosed with a stroke. In contrast, only one in 15 individuals whose parents remained together throughout their childhood exhibited a similar diagnosis. These alarming statistics underscore the profound impact that familial instability can exert on long-term health outcomes.

Mary Kate Schilke, the study’s first author and a university lecturer in the Psychology Department at Tyndale University, emphasized that even after adjusting for various known risk factors associated with stroke—such as smoking, physical inactivity, lower income and education levels, diabetes, depression, and a lack of social support—individuals who experienced parental divorce still faced a staggering 61% higher likelihood of stroke. This significant figure not only emphasizes the importance of considering familial background in assessing health risks but also raises questions about the underlying mechanisms contributing to this association.

The findings indicate that the strong correlation between parental divorce and stroke risk is not solely an anomaly but mirrors the effects of other established factors recognized in the medical community, such as diabetes and depression. This study builds upon previous research conducted nearly a decade ago, revealing similar outcomes in an entirely different population-based sample, thus affirming the consistency and validity of these findings.

One of the key challenges noted by the researchers is understanding the exact reasons behind this persistent link between parental divorce and later health complications. Senior author Esme Fuller-Thomson, a professor at the Factor-Inwentash Faculty of Social Work and the director of the Institute of Life Course and Aging at the University of Toronto, pointed out that while survey-based studies cannot definitively establish causality, the hope remains that these consistent findings could inspire further investigation into the mechanisms at play.

Importantly, the researchers took a comprehensive approach by excluding participants with a history of childhood abuse, which could potentially confound the results. Interestingly, the analysis revealed that even among individuals who had not experienced physical or sexual abuse in childhood and who had at least one adult present in their lives that made them feel safe, the risk of stroke remained significantly higher for those whose parents had divorced. This surprising finding suggests that the repercussions of parental divorce might transcend direct adverse childhood experiences, indicating deeper systemic influences.

Moreover, the study found that other forms of childhood adversity, including emotional abuse, neglect, household mental illness, substance abuse, or exposure to domestic violence, did not show a significant association with stroke risk. This specificity indicates that the psychological and physiological ramifications of parental divorce may be distinct from other types of childhood trauma, warranting focused attention in both research and clinical settings.

As the research community grapples with understanding the reasons behind these associations, the authors speculate on potential biological and sociological constructs contributing to heightened stroke risk among this demographic. From a biological standpoint, the stress associated with parental conflict and eventual separation during childhood may lead to sustained overproduction of stress hormones. This chronic physiological stress response could then impair the developing brain’s ability to manage adversity later in life, ultimately manifesting in physical health issues such as stroke.

The implications of this research extend beyond the individual, shedding light on broader societal patterns and healthcare considerations. If future studies continue to corroborate these associations between parental divorce and health risks, they could fundamentally reshape how healthcare professionals approach patient assessments and preventive strategies. Recognizing the potential influence of childhood family dynamics may provide an essential lens through which healthcare systems can enhance their outreach efforts for stroke prevention and education initiatives.

As the discourse surrounding mental and physical health continues to evolve, the findings from this study compel us to reconsider the long-term effects of childhood experiences on adult health. The growing awareness of how familial structures shape individual well-being is more crucial than ever, especially as society witnesses increasing divorce rates and the challenges those families face.

The optimism for further research is palpable, as the authors are hopeful that their findings will serve as a clarion call for interdisciplinary collaboration. By drawing attention to this underexplored area, they aim to invigorate interest among scholars, clinicians, and public health advocates. Greater understanding of how childhood experiences shape health trajectories could ultimately lead to more comprehensive strategies for health promotion and education, paving the way for better health outcomes in populations affected by familial instability.

In conclusion, the study published in PLOS One serves as a reminder of the intricate interplay between childhood experiences and adult health. The revelations regarding the association between parental divorce and increased stroke risk call for a deeper exploration into the underlying mechanisms, encouraging a holistic approach to health that acknowledges the significance of our early familial environments in shaping our long-term well-being.

Subject of Research: The impact of parental divorce on stroke risk in older adults.
Article Title: Parental divorce’s long shadow: Elevated stroke risk among older Americans.
News Publication Date: 22-Jan-2025.
Web References: DOI Link
References: N/A
Image Credits: N/A

Keywords: parental divorce, stroke risk, childhood adversity, health outcomes, psychosocial factors, aging, stress response, health research.